Akebia Therapeutics Inc (AKBA)
1.33
0.00 (0.00%)
USD |
NASDAQ |
Sep 27, 16:00
1.32
-0.01
(-0.75%)
After-Hours: 20:00
Akebia Therapeutics SG&A Expense (Annual): 100.23M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 100.23M |
| December 31, 2022 | 138.60M |
| December 31, 2021 | 174.14M |
| December 31, 2020 | 154.10M |
| December 31, 2019 | 149.46M |
| December 31, 2018 | 87.06M |
| Date | Value |
|---|---|
| December 31, 2017 | 27.01M |
| December 31, 2016 | 22.21M |
| December 31, 2015 | 18.50M |
| December 31, 2014 | 14.68M |
| December 31, 2013 | 7.031M |
| December 31, 2012 | 2.891M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
100.23M
Minimum
2023
174.14M
Maximum
2021
143.31M
Average
149.46M
Median
2019
SG&A Expense (Annual) Benchmarks
| Corcept Therapeutics Inc | 184.26M |
| Bioventus Inc | 303.88M |
| Eli Lilly and Co | 6.941B |
| Pfizer Inc | 14.77B |
| Cara Therapeutics Inc | 27.65M |